Biogen Shares Fall After It Scraps Alzheimer's Treatment

Biogen shares fall after it scraps Alzheimer's treatment

CNBC Television

Biogen shares drop after company scraps Alzheimer's drug

Biogen shares drop despite positive Alzheimer's drug results

CNBC Television

What Biogen halted its Alzheimer's drug trial means for biotech investors

CNBC Television

Cramer: Biogen's Alzheimer's treatment would be 'the biggest drug ever'

CNBC Television

Biogen shares drop as big clinics say they won't administer controversial Alzheimer's drug

CNBC Television

Biogen Analyst Sees No Clear Growth Driver to Replace Alzheimer's Drug

Bloomberg Television

Biogen shares spike after FDA approves Alzheimer's drug

CNBC Television

Analyst: It's unclear whether Biogen's new Alzheimer's drug will get approved

CNBC Television

Eisai-Biogen's Alzheimer's treatment drug receives FDA approval

Biogen Will Take Alzheimer's Therapy to FDA, Reviving Hope

Bloomberg Television

FDA approves Biogen Alzheimer's treatment

CNBC Television

Biogen and Eisai to reveal results of Alzheimer's drug trial

CNBC Television

What you need to know about Biogen’s new Alzheimer’s treatment

Biogen soars on promising results from Alzheimer's drug trial

CNBC Television

Biogen CEO: Alzheimer's drug shows positive results

CNBC Television

Biogen alzheimer's drug shows positive results

CNBC Television

FDA approves Biogen Alzheimer's drug, first new therapy for the disease in nearly two decades

CNBC Television

Alzheimer's drug decision day: FDA to decide on Biogen and Eisai treatments

CNBC Television

Biogen CEO Michel Vounatsos on seeking FDA approval for new Alzheimer's drug

CNBC Television